Factors related to treatment outcomes in low-risk gestational neoplasia


Turkmen O., BAŞARAN D., Karalok A., Kimyon G. C., Tasci T., ÜREYEN I., ...Daha Fazla

Tumori, cilt.103, sa.2, ss.177-181, 2017 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 103 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5301/tj.5000550
  • Dergi Adı: Tumori
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.177-181
  • Anahtar Kelimeler: Gestational-trophoblastic-neoplasia, Human-chorionic-gonadotropin, Methotrexate
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: To define the factors associated with methotrexate (MTX) resistance in patients with low-risk gestational trophoblastic neoplasia (GTN). Methods: A total of 63 patients with low-risk GTN according to International Federation of Gynecology and Obstetrics (FIGO) criteria were included. A total of 37 (58.7%) patients were treated with successive doses of 1 mg/kg intramuscular (IM) MTX on days 1, 3, 5, and 7, and 0.1 mg/kg IM folinic acid (FA) on days 2, 4, 6, and 8, until n-human chorionic gonadotropin (hCG) levels were normalized. After the -hCG value dropped to the normal level, an additional cycle of MTX/FA was administered. This protocol is defined as the standard protocol. In a watchful waiting protocol, the same 8-day IM MTX/FA regimen was given only once (n = 8) or twice (n = 18) to 26 (41.3%) patients and patients in whom -hCG values declined were subjected to follow-up and no additional cycles were administered as long as there was a decrease in -hCG value. Clinical response and factors affecting therapeutic outcomes were analyzed retrospectively. Results: Of 63 patients, 47 (74.3%) were cured with primary MTX/FA treatment irrespective of any protocol. Of the 16 patients who were not able to be treated with primary MTX/FA, 3 were treated with single-agent actinomycinD and 11 were treated with multi-agent chemotherapy. Univariate analysis showed that a pretreatment -hCG level of -5000 IU/L was related to reduced therapeutic response (p = 0.001). The FIGO score, antecedent gestational pathology, and treatment with standard or watchful waiting protocol were not related to treatment response. Conclusions: The level of -hCG prior to therapy is an important factor for predicting therapeutic outcomes. It should be noted that the success of the therapy decreases notably in case of high -hCG level.